FDA issues new policies for compounded drugs; U.S. doctors test CRISPR on cancer patients for the first time; Palio merged into GSW
Takeda announces deals worth more than $1 billion; biotech and pharma investments reached $10.5 billion in 2017; prescriptions for nerve pain on the rise
Ketchum, Ogilvy, Porter Novelli, Weber Shandwick, and FleishmanHillard are among the firms that have been awarded past Centers for Medicare and Medicaid Services IDIQ accounts.
Get America Covered is working to encourage consumers to sign up for coverage through the Affordable Care Act.
Mylan reports third-quarter loss; analysts say drug-pricing restrictions less likely under Trump; the FDA limits citizen petitions
Digital health technology for low-income consumers is growing and can be very effective when applied appropriately, a report finds.
Obama administration tells states they cannot restrict hep-C drugs; AstraZeneca says it will acquire ZS Pharma: Allergan CEO says drug discovery is too risky
Medicaid officials urged to expand access to hepatitis-C drugs; Perrigo is looking to make acquisitions; Sarepta's experimental therapy gets priority review
An analysis by Avalere Health says 10 breakthrough therapy drugs will account for billions in spending.
Novartis reported highest drug sales in 2014; state Medicaid programs spent $1.33 billion on hepatitis-C drugs; former FDA commissioner argues against shortening regulatory review times